And as studies have proven, Zepbound is more effective than Wegovy in achieving weight loss, and only Zepbound is has been proven effective and approved by the FDA for treating sleep apnea in patients with obesity. The lawsuit seeks to restore coverage of Zepbound for people on CVS Caremark plans and award other appropriate equitable relief. CVS Caremark says the suit is without merit. Well defend ourselves vigorously against those claims, David Whitrap, vice president of external affairs for CVS Health, said in an email
14 So nothing has changed about Medicare Part D coverage of GLP-1 drugs: They continue to only be covered if theyre prescribed to treat another condition, like diabetes, but not if theyre prescribed just to treat obesity
Whether it delivers on that promise is something the rest of this review will examine in detail, with real pricing data, honest feedback analysis, and comparisons to the providers you are likely also considering
One of the reasons GLP-1 medications have become increasingly popular is because one of the main benefits of them beyond blood sugar control is weight loss
Indeed, with marked volumetric deficits, we go from a healthy, youthful-looking face to a skeletonized face
